Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Caedo Oncology AS
AS
Active
Org 926135082
Gaustadalléen 21, 0349
Oslo
Wholesale of pharmaceutical and medical goods
·
NACE 4646
Est. 2020 · 5 years old
5 employees
Monitor
Share
Norway
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
Caedo Oncology AS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
NOK millions
2M
2M
1M
1M
0M
2021: 0M
0M
2021
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
2025: 2M
2M
2025
EBITDA
NOK millions
0M
-3M
-7M
-10M
-14M
2021: -3M
-3M
2021
2022: -8M (-167% vs 2021)
-8M
-167%
2022
2023: -11M (-37% vs 2022)
-11M
-37%
2023
2024: -3M (+73% vs 2023)
-3M
+73%
2024
2025: 0M (+100% vs 2024)
0M
2025
Income statement
NOK thousands
Item
2025
2024
2023
2022
2021
Revenue
1 837
0
0
0
0
Staff expenses
−723
−605
−2 091
−1 297
−238
EBITDA
−132
−3 492
−11 012
−8 386
−3 156
Depreciation & amort.
−134
−183
−175
−26
−0
EBIT
−265
−3 675
−11 187
−8 412
−3 156
Net financials
−454
65
10
−111
−7
Profit before tax
−719
−3 610
−11 177
−8 523
−3 163
Tax
−0
−0
−0
−0
−0
Net profit
−719
−3 610
−11 177
−8 523
−3 163
Balance sheet
NOK thousands
Item
2025
2024
2023
2022
2021
Total assets
45 946
42 573
16 253
11 509
1 561
Equity
34 536
28 582
14 417
10 278
1 023
Long-term debt
−7 690
5 835
0
278
0
Short-term debt
3 664
1 525
1 836
953
539
Total debt
3 719
7 360
1 836
1 231
539
Financial ratios
5-year trend
EBITDA margin
−7,2 %
This company
15,8 %
Market median
This company
Market median
146% below market
2021
2025
Equity ratio
75,2 %
This company
38,2 %
Market median
This company
Market median
97% above market
2021
2025
Return on equity
−2,1 %
This company
18,4 %
Market median
This company
Market median
111% below market
2021
2025
Net profit margin
−39,2 %
This company
8,1 %
Market median
This company
Market median
584% below market
2021
2025
Asset turnover
0,04×
This company
1,12×
Market median
This company
Market median
96% below market
2021
2025
Debt / equity
0,33×
This company
0,62×
Market median
This company
Market median
47% below market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
More on Caedo Oncology AS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
